Recent progress on third generation covalent EGFR inhibitors-Reference-Cited by-同舟云学术

Recent progress on third generation covalent EGFR inhibitors

Published:2016-04 Issue:8 Volume:26 Page:1861-1868
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Cheng Hengmiao,Nair Sajiv K.,Murray Brion W.

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference44 articles.

1. Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray, F. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. GLOBOCAN 2012 v1.1.

2. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

3. Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

4. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

5. Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and synthesis of novel Thiazolo[5,4-b]pyridine derivatives as potent and selective EGFR-TK inhibitors targeting resistance Mutations in non-small cell lung cancer;European Journal of Medicinal Chemistry;2024-10

2. Rational design and synthesis of 2,4‐dichloro‐6‐methyl pyrimidine derivatives as potential selective EGFR^T790M/L858R inhibitors for the treatment of non‐small cell lung cancer;Archiv der Pharmazie;2024-02-21

3. Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment;Bioorganic Chemistry;2024-02

4. Design and Synthesis of Novel Thiazolo[5,4-B]Pyridine Derivatives as Potent and Selective Egfr-Tk Inhibitors Targeting Resistance Mutations in Non-Small Cell Lung Cancer;2024

5. Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications;Cells;2023-12-25